IDH2 and acute myeloid leukemia: Unfortunately, the phase III trial IDHENTIFY (ClinicalTrials.gov (accessed on 7 February 2022), NCT02577406), which compared enasidenib to conventional treatments (best supportive care alone or in combination with azacytidine or low-dose or intermediate dose cytarabine) in R/R IDH2-mutated AML patients was announced to have missed the primary endpoint of OS in the enasidenib arm [218].